Categories: All postsLife Sciences

Buy Antibe Therapeutics for a 318 per cent return, says Echelon Wealth

Tagged with: ate
7 years ago
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Leave a Comment

Related Posts

Recent Posts

Is Elevate Service Group still a buy?

Beacon Securities analyst Donangelo Volpe says Elevate Service Group’s (Elevate Service Group Stock Quote, Chart, News, Analysts, Financials TSXV:SERV) first… [Read More]

12 hours ago

This analyst just raised his target on D-Wave to $40.00

Roth Capital Partners analyst Suji Desilva says D-Wave Quantum’s (D-Wave Quantum Stock Quote, Chart, News, Analysts, Financials NYSE:QBTS) first investor… [Read More]

13 hours ago

Firefly Aerospace has a “significant” opportunity, this analyst says

Roth Capital Partners analyst Suji Desilva says Firefly Aerospace’s (Firefly Aerospace Stock Quote, Chart, News, Analysts, Financials NASDAQ:FLY) latest equity… [Read More]

13 hours ago

Stifel raises price target on WELL Health Technologies

Stifel analyst Justin Keywood says WELL Health Technologies’ (WELL Health Technologies Stock Quote, Chart, News, Analysts, Financials TSX:WELL) $160-million imaging-clinic… [Read More]

14 hours ago

Celestica is a core AI play, this investor says

Velocity Investment Partners fund manager Brianne Gardner says Celestica (Celestica Stock Quote, Chart, News, Analysts, Financials TSX:CLS) remains a holding… [Read More]

1 day ago

This analyst just raised his price target on USA Rare Earth

Roth Capital Partners analyst Suji Desilva says USA Rare Earth (USA Rare Earth  Stock Quote, Chart, News, Analysts, Financials NASDAQ:USAR)… [Read More]

1 day ago